Attachment B						
Wisconsin Medicaid Fee-fo	Pharmacy	/				
Summary Comparison of Total	SFY04 Drug	Spend				
and SFY04 Non-Duals Drug Spe	end	•				
Excluding BadgerCare FFS, SeniorC		y Planning V	Vaiver			
SFY04 Summary	Paid		Recipients			Rx/Recip
Dual Eligibles	\$357,278,421			\$3,180		57.3
Non-Duals Only	\$207,292,856	3,131,553	208,151	\$996		15.0
Total	\$564,571,277			\$1,761	\$59.00	29.9
Non-Duals as % of Total	36.7%	32.7%	35.1%			
20 Highest Cost Classes - Non Duals	SFY04 Paid	SFY04 Rx's				
Antipsychotics - Atypicals	\$36,455,996		\$225.70			
Anticonvulsants	\$21,483,772	182,894				
Analgesics - Narcotics	\$11,848,280	224,355	\$52.81			
Antidepressants - SSRI's	\$9,537,357	141,267	\$67.51			
Agents for Ulcers - PPI's	\$7,947,912	79,655	\$99.78			
Stimulants	\$7,357,923	97,416	\$75.53			
Asthma - Preventative	\$7,454,773	70,599	\$105.59			
Lipotropes - Statins	\$4,289,167	50,256	\$85.35			
Antiretroviral	\$3,469,770	7,771	\$446.50			
Agents for RSV - Palivsumab	\$3,340,732	2,505	\$1,333.63			
Diabetes - Oral	\$3,306,581	66,011	\$50.09			
Antihemophelic	\$3,189,825	208	\$15,335.70			
Antidepressants - SNRI's	\$2,915,532	23,866	\$122.16			
Diabetes - Insulins	\$2,814,539	41,676	\$67.53			
NSAIDS - Cox 2 Inhibitors	\$2,734,769	27,809	\$98.34			
Antidepressants - NDRI's	\$2,662,345	26,829	\$99.23			
Immunosuppressants	\$2,225,326	6,715	\$331.40			
Asthma - Rescue	\$2,221,514	86,119	\$25.80			
Agents for Multiple Sclerosis	\$2,094,404		\$1,056.71			
Stimulants - Straterra	\$2,035,894		\$102.28			
Total \$\$ Top 20	\$139,386,411	1,319,360				
Total SFY04 Non-Dual Cost	\$207,292,856	3,131,553				
*Cost before CMS and supplemental reb	ates.					

Wisconsin Medicaid Fee-for-Service Pharmacy		
-		
Estimated Drug Spend Migrating to Medicare Part	ט	
by Therapy Class effective January 1, 2006		
	(Updated 5/20/05)	
Note: 63.3% of all drug spend will migrate to Medicare Part D		
effective 1/1/06. Classes showing migration above 63.3%		
disproportionately go to Medicare Part D. Classes showing migra	ation	
less than 63.3% disproportionately stay with Wisconsin Medicaid	!.	
	% of Drug Spend	All Funds Gross
	Going to Part D	\$\$ Staying in MA
Therapy Class	after 1/1/06	(using SFY04 \$\$)
ACE INHIBITORS	78.6%	\$976,036
ACE INHIBITORS/CCB COMBINATIONS	74.6%	\$231,688
ACETAMINOPHEN PRODUCTS	59.6%	\$96,336
AGENTS FOR ACNE	22.1%	\$150,343
AGENTS FOR ALS - RILUZOLE	62.7%	\$73,593
AGENTS FOR ALZHEIMER DISEASE	93.0%	
AGENTS FOR ANAPHYLAXIS	32.2%	
AGENTS FOR ASTHMA - PREVENTIVE	53.8%	\$7,454,773
AGENTS FOR ASTHMA - RESCUE	63.2%	\$2,221,514
AGENTS FOR BENIGN PROSTATIC HYPERTROPHY	86.9%	\$229,959
AGENTS FOR CHF - ALPHA/BETA BLOCKERS	76.4%	\$348,367
AGENTS FOR CHRONIC INFLAMMATION OF COLON	68.2%	\$211,907
AGENTS FOR COPD	74.7%	\$221,627
AGENTS FOR CYSTIC FIBROSIS	18.7%	\$575,609
AGENTS FOR DIABETES - GLUCOSE ELEVATING AGENTS	62.8%	\$91,056
AGENTS FOR DIABETES - INSULINS	67.6%	\$2,814,539
AGENTS FOR DIABETES - ORAL	73.2%	\$3,306,581
AGENTS FOR GALL STONES	65.6%	\$85,922
AGENTS FOR GLAUCOMA	88.6%	\$375,138
AGENTS FOR GOUT	83.8%	\$50,547
AGENTS FOR HEPATITIS	45.3%	
AGENTS FOR HYPERTHYROIDISM	67.1%	
AGENTS FOR IMPOTENCY	33.5%	
AGENTS FOR INTERSTITIAL CYSTITIS	69.6%	\$38,304
AGENTS FOR LEPROSY	52.8%	-
AGENTS FOR MIGRAINE - NON TRIPTANS	56.3%	
AGENTS FOR MIGRAINE - TRIPTANS	46.2%	
AGENTS FOR MULTIPLE SCLEROSIS	66.3%	1 1
AGENTS FOR OSTEOPOROSIS	87.1%	\$935,960
AGENTS FOR PARKINSON'S	85.1%	\$522,229
AGENTS FOR PCP	46.0%	\$38,004
AGENTS FOR PSORIASIS	64.3%	\$198,820
AGENTS FOR PULMONARY HYPERTENSION	43.4%	\$358,327
AGENTS FOR RA AND CROHN'S - INFLIXIMAB	85.8%	\$4,265
AGENTS FOR RHEUMATOID ARTHRITIS	62.6%	
AGENTS FOR RSV - PALIVISUMAB	0.2%	\$3,340,732
AGENTS FOR SMOKING CESSATION	52.0%	\$486,452
AGENTS FOR ULCERS - H PYLORI TREATMENT	46.6%	\$66,010
AGENTS FOR ULCERS - H2 RECEPTOR ANTAGONISTS	62.3%	\$910,040
AGENTS FOR ULCERS - OTHER	71.4%	\$59,919

	% of Drug Spend	All Funds Gross
	Going to Part D	\$\$ Staying in MA
Therapy Class	after 1/1/06	(using SFY04 \$\$)
AGENTS FOR ULCERS - PROTON PUMP INHIBITORS	72.0%	\$7,947,912
AGENTS FOR URINARY SPASM	80.0%	\$1,264,981
AGENTS FOR WEIGHT LOSS	47.8%	\$293,273
AGENTS FOR WOUND HEALING	85.9%	\$199,043
ALPHA BLOCKERS	84.5%	\$34,338
AMINOGLYCOSIDES	32.9%	\$415,412
ANALGESICS - BUTALBITAL	50.4%	\$32,031
ANALGESICS - NARCOTIC ANESTHETICS	87.2%	\$157
ANALGESICS - NARCOTICS	64.4%	\$11,848,280
ANALGESICS - NSAIDS - COX2 INHIBITORS	76.1%	\$2,734,769
ANALGESICS - NSAIDS - NON-COX2 INHIBITORS	62.3%	
ANALGESICS - SALICYLATES	75.4%	
ANDROGENS/ANABOLIC STEROIDS	60.4%	
ANGIOTENSIN RECEPTOR BLOCKERS	79.0%	
ANORECTAL PREPARATIONS	67.1%	
ANTACIDS	76.7%	. ,
ANTHELMINTICS	24.5%	-
ANTI-ANXIETY AGENTS - BENZODIAZEPINES	63.6%	. ,
ANTI-ANXIETY AGENTS - BUSPIRONE	69.4%	
ANTI-ANXIETY AGENTS - OTHER	79.9%	-
ANTIARRHYTHMICS	80.0%	
ANTICOAGULANTS - HEPARIN/RELATED	53.2%	-
ANTICOAGULANTS - ORAL	83.6%	
ANTICONVULSANTS	57.3%	
ANTIDEPRESSANTS - A2RAS	79.5%	
ANTIDEPRESSANTS - MAO INHIBITORS	82.9%	
ANTIDEPRESSANTS - NDRIS	49.6%	
ANTIDEPRESSANTS - OTHER	63.7%	
ANTIDEPRESSANTS - SARIS	64.0%	
ANTIDEPRESSANTS - SNRIS	60.6%	
ANTIDEPRESSANTS - SSRIS	65.4%	
ANTIDEPRESSANTS - TRICYCLICS	62.9%	
ANTIDIARRHEALS	73.1%	
ANTIDOTES	3.7%	
ANTIEMETIC/ANTIVERTIGO - ANTISEROTONIN AGENTS	49.3%	
ANTIEMETIC/ANTIVERTIGO - ANTISEROTORIN AGENTS ANTIEMETIC/ANTIVERTIGO - DRONABINOL	52.7%	
ANTIEMETIC/ANTIVERTIGO - DISCRABINOL ANTIEMETIC/ANTIVERTIGO - MISCELLANEOUS	59.7%	
ANTIFUNGALS	42.1%	
ANTIFUNGALS ANTI-INFECTIVES	46.5%	
ANTIFUNGALS ANTI-INFECTIVES ANTIFUNGALS DERMATOLOGIC	68.8%	
		-
ANTIHEMOPHILIC FACTORS	0.7%	
ANTIHISTAMINES - NON-SEDATING ANTIHISTAMINES - NON-SEDATING COMBINATION	54.7%	
	53.1%	-
ANTIHISTAMINES - SEDATING COMPINIATION	53.0%	-
ANTIHISTAMINES - SEDATING COMBINATION	32.2%	
ANTI-INFECTIVES DEPMATOLOGIC	60.3%	
ANTI-INFECTIVES DERMATOLOGIC	47.0%	
ANTIINFECTIVES OPHTHALMIC	59.4%	
ANTI-INFECTIVES OTIC	31.7%	\$202,679

	% of Drug Spend	All Funds Gross
	Going to Part D	\$\$ Staying in MA
Therapy Class	after 1/1/06	(using SFY04 \$\$)
ANTIMALARIAL	75.8%	\$123,447
ANTINEOPLASTICS	66.1%	\$998,700
ANTIPLATELETS - AGGREGATION INHIBITORS	82.7%	\$1,242,908
ANTIPSYCHOTICS - ATYPICALS	62.7%	\$36,455,996
ANTIPSYCHOTICS - NON-PHENOTHIAZINE	67.4%	\$603,056
ANTIPSYCHOTICS - PHENOTHIAZINES	69.8%	\$261,992
ANTIRETROVIRAL	50.8%	\$3,469,770
ANTISEPTICS	64.6%	\$36,565
ANTISPASMODICS/ANTICHOLINERGICS	56.3%	\$204,386
ANTITUBERCULAR	61.0%	\$52,143
ANTIVIRAL	54.1%	
BETA BLOCKERS	77.0%	-
BULK CHEMICAL/ADJUVANTS	41.4%	
CALCIUM	66.4%	
CALCIUM CHANNEL BLOCKERS	80.0%	
CARBOHYDRATES	56.6%	
CEPHALOSPORINS	51.1%	-
CHOLINERGICS	79.6%	. , ,
CONTRACEPTIVES ORAL	23.6%	
CONTRACEPTIVES OTHER	11.0%	
COUGH AND COLD	50.3%	
COUGH SUPPRESSANTS - NARCOTIC	53.6%	
DECONGESTANTS OPHTHALMIC	72.4%	
DENTAL AGENTS	48.6%	
DERMATOLOGIC IMMUNOSUPPRESSANTS	34.6%	
DIAGNOSTICS	48.5%	
DIGESTIVE ENZYMES	43.8%	
DIGITALIS GLYCOSIDES	86.2%	
DISULFIRAM	64.5%	
DIURETICS COMBINATION	78.4%	
DIURETICS LOOP	85.4%	
DIURETICS OTHER	67.9%	
DIURETICS POTASSIUM SPARING	74.2%	
DIURETICS THIAZIDE	80.0%	. ,
DMS/DME	21.6%	
ESTROGENS	64.7%	
ETHANOL	0.3%	
FOLATE ANTAGONISTS	84.0%	
GENERAL ANESTHETICS	71.5%	
GLUCOCORTICOIDS	61.8%	-
GROWTH HORMONE	4.1%	
HEMORRHEOLOGIC AGENTS	87.6%	
HEMOSTATICS - ANTIFIBRINOLYTIC	29.3%	
HYPOTENSIVES - CENTRALLY ACTING	64.0%	
HYPOTENSIVES - CENTRALLY ACTING HYPOTENSIVES - VASODILATORS	78.6%	
		-
HYPOTENSIVES OTHER	29.9%	
IMMUNE GLOBULINS	50.4%	
IMMUNOMODULATORS	29.0%	
IMMUNOSUPPRESSANTS	47.6%	\$2,225,326

	% of Drug Spend	All Funds Gross
	Going to Part D	\$\$ Staying in MA
Therapy Class	after 1/1/06	(using SFY04 \$\$)
INTESTINAL MOTILITY STIMULANTS	70.1%	\$82,808
LAXATIVES	71.0%	\$515,494
LINCOSAMIDES	47.8%	\$144,393
LIPIDS PARENTERAL	38.5%	\$60,083
LIPOTROPES - NON STATINS	72.7%	\$783,302
LIPOTROPES - STATINS	77.7%	\$4,289,167
LITHIUM	54.7%	
LOCAL ANESTHETICS	72.3%	\$32,671
LUBRICANTS OPHTHALMIC	90.7%	\$25,974
MACROLIDES	41.0%	\$1,656,072
MAGNESIUM	28.9%	\$5,373
MAST CELL STABILIZERS OPHTHALMIC	72.2%	\$10,101
METRONIDAZOLE	38.6%	\$38,040
MINERALS	51.7%	\$73,712
MYDRIATICS	66.5%	\$7,282
NARCOTIC ANTAGONISTS	56.2%	\$65,245
NASAL - AGENTS FOR RHINORRHEA	70.6%	\$51,558
NASAL DECONGESTANTS	0.0%	\$94
NASAL MUPIROCIN	67.0%	\$2,302
NASAL STEROIDS	59.4%	\$1,371,129
NITAZOXANIDE	0.5%	\$572
NITRATES	90.2%	
NITROFURANS	72.0%	
NON-LISTED PA DRUGS	83.8%	\$18,030
NON-NDC COMPOUND DRUGS	36.1%	\$246,779
NSAIDS OPHTHALMIC	79.8%	\$22,990
OPHTHALMIC STEROIDS	78.3%	\$32,927
OTHER ANTI-INFECTIVES	55.7%	\$436,746
OTHER CARDIOVASCULAR	77.1%	\$95,064
OTHER DERMATOLOGIC	66.6%	\$695,995
OTHER ELECTROLYTES	70.2%	\$36,072
OTHER ENDOCRINE	76.1%	\$30,303
OTHER GASTROINTESTINAL	60.1%	\$220,800
OTHER NUTRITION	25.2%	
OTHER OPHTHALMIC	78.3%	
OTHER OTIC	22.9%	
OTHER RENAL	74.5%	
OTHER RESPIRATORY	27.4%	
OVULATION STIMULANTS	0.0%	
PEDICULOCIDES	23.1%	·
PENICILLINS	33.4%	
PHARMACEUTICAL CARE	69.0%	
PHOSPHATE	26.3%	
PHOSPHATE BINDER	86.4%	
PITUITARY HORMONES	51.5%	
PLASMA PROTEINS/EXPANDERS	0.0%	
PLATELET PROLIFERATION STIMULANTS	80.1%	
POSITIVE INOTROPES	51.9%	
POTASSIUM	85.7%	\$338,294

	% of Drug Spend All Funds Gro	
	Going to Part D	\$\$ Staying in MA
Therapy Class	after 1/1/06	(using SFY04 \$\$)
PROGESTINS	55.6%	\$44,041
PROTEIN REPLACEMENT	48.7%	\$113,626
QUINOLONES	70.7%	\$1,498,233
RBC STIMULANTS	75.3%	\$735,988
RETINOIDS	26.6%	\$332,081
SEDATIVE HYPNOTICS	62.6%	\$151,153
SEDATIVE HYPNOTICS - ZALEPLON	59.6%	\$1,891,441
SKELETAL MUSCLE RELAXANTS	59.3%	\$1,291,697
SODIUM	48.2%	\$237,307
SOLUTIONS	6.6%	\$84,391
STEROID ANTIBIOTIC COMBO OPHTHALMIC	71.7%	\$63,851
STEROID ANTIBIOTIC COMBO OTIC	32.5%	\$148,868
STEROIDS DERMATOLOGIC	60.7%	\$513,143
STIMULANTS	14.4%	\$7,357,923
STIMULANTS ATOMOXETINE	8.9%	\$2,035,894
SULFONAMIDES	55.4%	\$149,164
SYSTEMIC ENZYME INHIBITORS	57.4%	\$212,084
SYSTEMIC ENZYME REPLACEMENT	3.1%	\$465,654
TETRACYCLINES	61.5%	\$274,483
THROMBOLYTIC ENZYMES	31.6%	\$3,059
THYROID REPLACEMENT	78.5%	\$638,985
TOPICAL MUPIROCIN	58.7%	\$78,441
URINARY ANTI-INFECTIVES	78.2%	\$30,890
URINARY TRACT ANALGESIC	62.5%	\$19,313
VACCINES	33.3%	\$368
VAGINAL PREPARATIONS	50.1%	\$297,614
VANCOMYCIN	58.2%	\$124,907
VASOPRESSOR HORMONES	25.7%	\$986,071
VITAMINS	72.5%	\$56,916
VITAMINS B12	91.2%	\$8,599
VITAMINS FOLIC ACID	70.5%	\$59,121
VITAMINS PEDIATRIC	0.0%	\$49,301
VITAMINS PRENATAL	5.8%	\$236,939
WATER FOR INJECTION OR INHALATION	35.9%	\$25,897
WBC STIMULANTS	37.3%	
Takal All Davins	00.004	#007.000.050
Total - All Drugs	63.3%	\$207,292,856

Attachment B

Wisconsin SeniorCare Pharmacy Summary of Total SFY04 Drug Spend

20 Highest Cost Classes	SF	Y04 Paid	SFY04 Rx's	Со	st/Rx*
LIPOTROPES - STATINS	\$	13,303,869	198,152	\$	67.14
AGENTS FOR ULCERS - PROTON PUMP INHIBITORS	\$	8,370,960	75,947	\$	110.22
CALCIUM CHANNEL BLOCKERS	\$	5,678,916	164,180	\$	34.59
AGENTS FOR OSTEOPOROSIS	\$	5,270,596	90,250	\$	58.40
ANTIPLATELETS - AGGREGATION INHIBITORS	\$	4,986,284	49,607	\$	100.52
AGENTS FOR ASTHMA - PREVENTIVE	\$	4,621,651	51,380	\$	89.95
AGENTS FOR DIABETES - ORAL	\$	4,490,190	126,631	\$	35.46
ANALGESICS - NSAIDS - COX2 INHIBITORS	\$	4,382,758	55,258	\$	79.31
ANTIDEPRESSANTS - SSRIS	\$	4,075,997	76,944	\$	52.97
ANGIOTENSIN RECEPTOR BLOCKERS	\$	3,771,181	86,824	\$	43.43
ANALGESICS - NARCOTICS	\$	3,618,861	106,437	\$	34.00
AGENTS FOR ALZHEIMER DISEASE	\$	3,163,659	25,404	\$	124.53
ACE INHIBITORS	\$	2,553,569	206,158	\$	12.39
ANTICONVULSANTS	\$	2,516,615	34,814	\$	72.29
ANTIPSYCHOTICS - ATYPICALS	\$	2,512,303	16,944	\$	148.27
AGENTS FOR GLAUCOMA	\$	2,321,959	58,577	\$	39.64
AGENTS FOR URINARY SPASM	\$	2,103,930	32,742	\$	64.26
ANTINEOPLASTICS	\$	1,988,571	20,546	\$	96.79
BETA BLOCKERS	\$	1,678,795	225,876	\$	7.43
LIPOTROPES - NON STATINS	\$	1,606,325	36,372	\$	44.16
Total Top 20	\$	83,016,989	1,739,043	\$	47.74
Total SFY04 Cost - All Classes	\$	111,095,878	3,094,772	\$	35.90

^{*}Cost before CMS and supplemental rebates.